Hematologic Malignancy
AL Amyloidosis
CI-CAN-00008703Explore in graph →
HematologicNon-malignant31 active trials
- NCIt
- C158963
- MeSH
- D000075363
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00008703Explore in graph →
Clinical trials
79 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06768489 | A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma | recruiting | Phase 1 | 276 | Janssen Research & Development, LLCINDUSTRY | 5 | Sep 25, 2026 | clinicaltrials |
| NCT05145816 | Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 37 | University of Texas Southwestern Medical CenterOTHER |
| 1 |
| Aug 19, 2026 |
| clinicaltrials |
| NCT06569147 | Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis | recruiting | Phase 1 / Phase 2 | 49 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT04847453 | Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | active not recruiting | Phase 1 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04754945 | Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis | active not recruiting | Phase 1 | 11 | Emory UniversityOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06097832 | Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis(NEXICART-2) | active not recruiting | Phase 1 / Phase 2 | 45 | Nexcella Inc.INDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05451771 | Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis | active not recruiting | Phase 1 / Phase 2 | 53 | Columbia UniversityOTHER | 1 | Jul 10, 2026 | clinicaltrials |
| NCT07081646 | A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.(ALACRITY) | recruiting | Phase 1 / Phase 2 | 91 | Alexion Pharmaceuticals, Inc.INDUSTRY | 3 | Jul 2, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials